NCT01390350View on ClinicalTrials.gov

Ilaris® Effects in Schnitzler Syndrome (ILESCH)

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

December 21, 2017

Study Completion Date

May 31, 2018

Conditions
Schnitzler Syndrome
Interventions
DRUG

Canakinumab

150mg subcutaneous injections on day 0

DRUG

Placebo

150mg subcutaneous injections on day 0

Trial Locations (5)

10117

Allergie-Centrum-Charité, Charité University, Berlin

Unknown

Dept. of Dermatology, Klinikum Darmstadt, Darmstadt

Dept. of Dermatology, University Heidelberg, Heidelberg

Dept. of Dermatology, University Münster, Münster

Dept. of Dermatology, University Tübingen, Tübingen

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Charite University, Berlin, Germany

OTHER